Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans

biotech lab

Kezar Life Sciences, Inc. (NASDAQ:KZR) announced regulatory updates and began exploring strategic alternatives.

The company has retained TD Cowen to support it with the strategic review process.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.